Medicare Enrolled
Dr. David Berz, MD, PHD, MPH
Hematology & Oncology · Los Angeles, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Berz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Berz?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Berz
Dr. David Berz is a hematology & oncology specialist in Los Angeles, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Berz performed 5,643 Medicare services across 863 unique beneficiaries.
Between the years covered by Open Payments, Dr. Berz received a total of $479,367 from 80 pharmaceutical and/or device companies across 1153 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Berz is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 32% volume in CA
$479,367 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,643
Medicare services
Top 32% in CA for hematology & oncology
863
Unique beneficiaries
$34
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~314 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (ondansetron/Zofran) | 1,624 | $0 | $9 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,418 | $0 | $9 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
469 | $109 | $250 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
327 | $26 | $99 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
272 | $100 | $345 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
242 | $154 | $349 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
210 | $120 | $299 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
175 | $2 | $13 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
173 | $12 | $50 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
120 | $27 | $111 |
| New patient office visit, complex (60-74 min) | 102 | $188 | $400 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
88 | $7 | $17 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
87 | $11 | $48 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
69 | $1 | $10 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
57 | $8 | $10 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
56 | $52 | $167 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
52 | $1 | $12 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
49 | $74 | $200 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
27 | $145 | $650 |
| Same-day hospital admission and discharge, moderate complexity This code covers initial hospital care for a patient admitted and discharged on the same day. It applies when the visit involves moderate medical decision making and lasts at least 70 minutes. |
26 | $128 | $433 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
15.7% high complexity
60.7% medium
23.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$479,367
Total received (2018-2024)
Avg $68,481/year across 7 years
Top 2% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
80
Companies
1,153
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$434,473 (90.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$31,793 (6.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,101 (2.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$10,874
2023
$60,515
2022
$101,453
2021
$85,244
2020
$59,744
2019
$100,892
2018
$60,645
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Boehringer Ingelheim International GmbH
$4,192
EMD Serono, Inc.
$4,130
AstraZeneca Pharmaceuticals LP
$284
Janssen Biotech, Inc.
$255
PFIZER INC.
$176
Tempus AI, Inc
$156
Merck Sharp & Dohme LLC
$155
Aveo Pharmaceuticals, Inc.
$135
Regeneron Healthcare Solutions, Inc.
$133
Daiichi Sankyo Inc.
$131
Amgen Inc.
$102
SUN PHARMACEUTICAL INDUSTRIES INC.
$100
Gilead Sciences, Inc.
$98
GE HEALTHCARE
$94
Novartis Pharmaceuticals Corporation
$89
Takeda Pharmaceuticals U.S.A., Inc.
$81
Dendreon Pharmaceuticals LLC
$74
Astellas Pharma US Inc
$73
E.R. Squibb & Sons, L.L.C.
$71
JAZZ PHARMACEUTICALS INC.
$63
Amneal Pharmaceuticals LLC
$52
ARRAY BIOPHARMA INC
$44
Bayer Healthcare Pharmaceuticals Inc.
$43
Eisai Inc.
$40
SpringWorks Therapeutics, Inc.
$35
PROGENICS PHARMACEUTICALS, INC.
$23
Genentech USA, Inc.
$23
Alexion Pharmaceuticals, Inc.
$21
Top 3 companies account for 79.1% of 2024 payments
All-time payments by company (2018-2024) ›
JAZZ PHARMACEUTICALS INC.
$143,745
Sun Pharmaceutical Industries Inc.
$70,147
Genentech USA, Inc.
$68,562
AstraZeneca Pharmaceuticals LP
$43,452
SUN PHARMACEUTICAL INDUSTRIES INC.
$33,969
Merck Sharp & Dohme Corporation
$29,012
EMD Serono, Inc.
$28,593
Boehringer Ingelheim International GmbH
$13,979
Mirati Therapeutics, Inc.
$13,279
Novartis Pharmaceuticals Corporation
$10,878
Amgen Inc.
$5,761
Takeda Pharmaceuticals U.S.A., Inc.
$3,401
Helsinn Therapeutics (U.S.), Inc.
$2,784
Jazz Pharmaceuticals Inc.
$1,325
PFIZER INC.
$1,144
Pfizer Inc.
$1,000
E.R. Squibb & Sons, L.L.C.
$989
Janssen Biotech, Inc.
$628
Ipsen Biopharmaceuticals, Inc
$314
Boehringer Ingelheim Pharma GmbH & Co.KG
$308
Daiichi Sankyo Inc.
$298
Eisai Inc.
$282
Gilead Sciences, Inc.
$268
EISAI INC.
$225
Bayer HealthCare Pharmaceuticals Inc.
$217
Astellas Pharma US Inc
$209
Merck Sharp & Dohme LLC
$198
Teva Pharmaceuticals USA, Inc.
$175
Regeneron Healthcare Solutions, Inc.
$159
Aveo Pharmaceuticals, Inc.
$158
Tempus AI, Inc
$156
Incyte Corporation
$151
Puma Biotechnology, Inc.
$143
Celgene Corporation
$141
Pinnacle Biologics, Inc
$140
Seattle Genetics, Inc.
$139
Novocure Inc.
$139
GENZYME CORPORATION
$133
NOVARTIS PHARMACEUTICALS CORPORATION
$131
BeiGene USA, Inc.
$127
INSYS Therapeutics Inc
$123
Karyopharm Therapeutics Inc.
$113
Pharmacyclics LLC, An AbbVie Company
$110
Seagen Inc.
$109
Alexion Pharmaceuticals, Inc.
$107
Amneal Pharmaceuticals LLC
$103
Dendreon Pharmaceuticals LLC
$102
GlaxoSmithKline, LLC.
$101
Array BioPharma Inc.
$97
Exelixis Inc.
$96
Blueprint Medicines Corporation
$96
GE HEALTHCARE
$94
Lilly USA, LLC
$93
TerSera Therapeutics LLC
$92
PUMA BIOTECHNOLOGY, INC.
$91
ARRAY BIOPHARMA INC
$89
ADC Therapeutics America, Inc.
$82
TESARO, Inc.
$77
Taiho Oncology, Inc.
$67
Kyowa Kirin, Inc.
$61
MEDIVATION FIELD SOLUTIONS LLC
$57
Apellis Pharmaceuticals, Inc.
$50
G1 Therapeutics, Inc.
$43
Myriad Genetic Laboratories, Inc.
$43
Bayer Healthcare Pharmaceuticals Inc.
$43
Sobi, Inc
$39
SpringWorks Therapeutics, Inc.
$35
AVEO Pharmaceuticals, Inc.
$32
Heron Therapeutics, Inc.
$32
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$29
AbbVie Inc.
$27
Pharmacyclics LLC, an AbbVie Company
$27
PROGENICS PHARMACEUTICALS, INC.
$23
ABBVIE INC.
$23
MorphoSys, US Inc.
$20
Global Blood Therapeutics, Inc.
$20
Dova Pharmaceuticals
$18
Foundation Medicine, Inc.
$17
Clovis Oncology, Inc.
$17
Boehringer Ingelheim Pharmaceuticals, Inc.
$9
Top 3 companies account for 58.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALUNBRIG · AVASTIN · AYVAKIT · Alecensa · Avastin · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRACAnalysis · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CINVANTI · COSELA · CREON · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELITEK · ENHERTU · EXKIVITY · Empaveli · Enhertu · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAVRETO · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · JADENU · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · LifeVest · Lonsurf · MEKINIST · MONJUVI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · ODOMZO · OGSIVEO · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Odomzo · Oncology · PADCEV · PIQRAY · POTELIGEO · PROMACTA · PROVENGE · PYLARIFY · Photofrin · ROZLYTREK · RYBREVANT · RYDAPT · Revlimid · Rubraca · SARCLISA · SOLIRIS · SOMATULINE DEPOT · SUSTOL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TABRECTA · TAFINLAR · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TEPMETKO · TRUSELTIQ · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tecentriq · Trodelvy · ULTOMIRIS · VELCADE · VENCLEXTA · VERZENIO · Vitrakvi · Vyloy · XALKORI · XPOVIO · XT CDX · XTANDI · Xospata · Xtandi · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · ZYKADIA · ZYTIGA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (91%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for hematology & oncology in CA.
Geographic Context
Hematology & oncology specialists within 10 mi
355
Per 100K population
3.6
County median income
$87,760
Nearest hospital
KAISER FOUNDATION HOSPITAL - WEST LA
2.0 mi
2.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Berz is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 2% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Berz experienced with anti-nausea injection (ondansetron/zofran)?
Based on Medicare claims data, Dr. Berz performed 1,624 anti-nausea injection (ondansetron/zofran) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Berz receive payments from pharmaceutical companies?
Yes. Dr. Berz received a total of $479,367 from 80 companies across 1,153 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Berz's costs compare to other hematology & oncology specialists in Los Angeles?
Dr. Berz's average Medicare payment per service is $34. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Berz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Los Angeles
Browse hematology & oncology specialists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
JAZZ PHARMACEUTICALS INC. Payments to Doctors
See all physicians who received payments from JAZZ PHARMACEUTICALS INC.
By company
Sun Pharmaceutical Industries Inc. Payments to Doctors
See all physicians who received payments from Sun Pharmaceutical Industries Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology